TY - JOUR
T1 - Lenalidomide in relapsed or refractory mantle cell lymphoma
T2 - Overview and perspective
AU - Desai, Madhav
AU - Newberry, Kate
AU - Zhishuo, Z.
AU - Wang, Michael
AU - Zhang, Liang
PY - 2014/6
Y1 - 2014/6
N2 - Lenalidomide, a novel immunomodulatory agent, was approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome and relapsed multiple myeloma. Data from preclinical studies paved the way for clinical trials of lenalidomide in mantle cell lymphoma (MCL). Initial phase I and II clinical trials of lenalidomide alone and as part of combination regimens in patients with relapsed/refractory MCL have shown promising results. Its immunomodulatory, T cell costimulatory, anti-inflammatory and anti-angiogenic actions working together in the tumor cell microenvironment seem to be responsible for its enhanced antitumor efficacy. Lenalidomide's nature of action and safety profile favor it over other agents studied in relapsed/refractory MCL. This review summarizes the data from preclinical and clinical studies of lenalidomide in relapsed/refractory MCL and compares the results with those of other novel agents being used for relapsed/refractory MCL.
AB - Lenalidomide, a novel immunomodulatory agent, was approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome and relapsed multiple myeloma. Data from preclinical studies paved the way for clinical trials of lenalidomide in mantle cell lymphoma (MCL). Initial phase I and II clinical trials of lenalidomide alone and as part of combination regimens in patients with relapsed/refractory MCL have shown promising results. Its immunomodulatory, T cell costimulatory, anti-inflammatory and anti-angiogenic actions working together in the tumor cell microenvironment seem to be responsible for its enhanced antitumor efficacy. Lenalidomide's nature of action and safety profile favor it over other agents studied in relapsed/refractory MCL. This review summarizes the data from preclinical and clinical studies of lenalidomide in relapsed/refractory MCL and compares the results with those of other novel agents being used for relapsed/refractory MCL.
KW - immunomodulatory agents
KW - lenalidomide
KW - mantle cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84993815526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84993815526&partnerID=8YFLogxK
U2 - 10.1177/2040620714532124
DO - 10.1177/2040620714532124
M3 - Review article
C2 - 24883181
AN - SCOPUS:84993815526
SN - 2040-6207
VL - 5
SP - 91
EP - 101
JO - Therapeutic Advances in Hematology
JF - Therapeutic Advances in Hematology
IS - 3
ER -